EverSource Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

EverSource Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.6K	Sell	1,315 -3,154	-71%	-$59.7K	﹤0.01%	2310
2026 Q1	$97.2K	Sell	4,469 -1,453	-25%	-$28.1K	﹤0.01%	1444
2025 Q4	$127K	Buy	5,922 +4,817	+436%	+$102K	﹤0.01%	1186
2025 Q3	$21.3K	Buy	1,105 +1,091	+7,793%	+$19.4K	﹤0.01%	2321
2025 Q2	$239	Sell	14 -119	-89%	-$5.08K	﹤0.01%	4031
2025 Q1	$8.49K	Buy	133 +17	+15%	+$1.79K	﹤0.01%	2202
2024 Q4	$14.1K	Buy	116 +78	+205%	+$9.56K	﹤0.01%	1823
2024 Q3	$4.75K	Buy	38 +1	+3%	+$138	﹤0.01%	2248
2024 Q2	$5.26K	Buy	37 +12	+48%	+$1.54K	﹤0.01%	2206
2024 Q1	$3.17K	Hold	25	–	–	﹤0.01%	2229
2023 Q4	$2.41K	Sell	25 -2	-7%	-$192	﹤0.01%	2116
2023 Q3	$3.27K	Sell	27 -3	-10%	-$339	﹤0.01%	1860
2023 Q2	$3.44K	Buy	30 +13	+76%	+$1.68K	﹤0.01%	1879
2023 Q1	$2.34K	Hold	17	–	–	﹤0.01%	1887
2022 Q4	$2.2K	Hold	17	–	–	﹤0.01%	1880
2022 Q3	$2K	Hold	17	–	–	﹤0.01%	1722
2022 Q2	$1K	Hold	17	–	–	﹤0.01%	1670
2022 Q1	$1K	Hold	17	–	–	﹤0.01%	1666
2021 Q4	$2K	Buy	+17	New	+$1.45K	﹤0.01%	1624

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

EverSource Wealth Advisors's SRPT Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Sarepta Therapeutics (SRPT) stake by 71% in Q2 2026, selling an estimated $59.7K and leaving 1,315 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

EverSource Wealth Advisors first reported a position in SRPT in Q4 2021 and has held it in 19 quarters since. The position peaked at $127K in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

EverSource Wealth Advisors held 1,315 shares of Sarepta Therapeutics worth $23.6K as of Q2 2026.
EverSource Wealth Advisors sold 3,154 Sarepta Therapeutics shares in Q2 2026, an estimated $59.7K.
Sarepta Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2310 holding.
EverSource Wealth Advisors first reported a position in Sarepta Therapeutics in Q4 2021 and has held it in 19 quarters since.
EverSource Wealth Advisors's Sarepta Therapeutics position peaked at $127K in Q4 2025.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.